Doxecitine/doxribtimine
Doxecitine (top) and doxribtimine (bottom) | |
| Combination of | |
|---|---|
| Doxecitine | Pyrimidine nucleoside |
| Doxribtimine | Pyrimidine nucleoside |
| Clinical data | |
| Trade names | Kygevvi |
| AHFS/Drugs.com | kygevvi |
| License data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Doxecitine/doxribtimine, sold under the brand name Kygevvi, is a fixed-dose combination medication used for the treatment of thymidine kinase 2 deficiency. It contains the pyrimidine nucleosides, doxecitine (deoxycytidine) and doxribtimine (thymidine).
The most common side effects include diarrhea, vomiting, increase in liver enzymes, and abdominal pain.
Doxecitine/doxribtimine was approved for medical use in the United States in November 2025.